GlassScriptPhysician profile
Gabrielle Harding
NPI 1952068512
$5,958.27
in general payments reported to CMS, 2019-2025
34 companies · $988 in 2025
The $988 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $30.04 · 2022: $1,216 · 2023: $1,831 · 2024: $1,894 · 2025: $988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,533 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,533.02 |
| Education | $179.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $920.22 | 2022-2025 | |
| Amgen INC. | $740.71 | 2022-2025 | Otezla, Otezla, Enbrel |
| Janssen Biotech, INC. | $331.46 | 2023-2025 | Tremfya |
| Genzyme Corporation | $325.38 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $295.55 | 2023-2025 | Sotyktu |
| Ucb, INC. | $293.17 | 2024-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $291.82 | 2022-2025 | Dupixent, Libtayo |
| Glaxosmithkline, LLC. | $252.74 | 2022-2023 | Nucala |
| Sun Pharmaceutical Industries INC. | $232.39 | 2023-2025 | Ilumya, Absorica Ld, Winlevi |
| Novartis Pharmaceuticals Corporation | $223.88 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $212.54 | 2022-2023 | Tezspire |
| Leo Pharma INC. | $204.31 | 2023-2025 | Adbry |
| Incyte Corporation | $174.20 | 2023-2024 | Opzelura |
| Dermavant Sciences, INC. | $160.76 | 2024 | Vtama |
| Kaleo, INC. | $160.00 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $136.32 | 2022-2023 | Orladeyo |
| Galderma Laboratories, L.P. | $125.00 | 2024 | |
| Csl Behring | $121.80 | 2022-2023 | Hizentra |
| Lilly USA, LLC | $94.18 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $90.39 | 2022-2023 | |
| Genentech USA, INC. | $84.03 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.17 | 2023-2024 | Spevigo, Cyltezo |
| Organon LLC | $80.84 | 2025 | Vtama |
| Grifols USA, LLC | $60.25 | 2022-2023 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $50.28 | 2022 | |
| Alk-Abello, INC | $35.61 | 2022-2023 | Grastek, Ragwitek, Odactra |
| Mayne Pharma Commercial LLC | $31.22 | 2024 | |
| Bio Products Laboratory USA, INC. | $30.75 | 2022 | |
| Merck Sharp & Dohme LLC | $25.26 | 2023 | Keytruda |
| Sandoz INC. | $20.10 | 2024 | Hyrimoz |
| Verrica Pharmaceuticals INC. | $19.19 | 2023 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.82 | 2024 | Arazlo, Cabtreo, Jublia |
| Pharming Healthcare, INC. | $17.87 | 2023 | Ruconest |
| Arcutis Biotherapeutics, INC. | $16.06 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabrielle Harding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.